Randomized, multicenter, open-label, phase 3 study of mirvetuximab
soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-positive recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab
Trial Number
NCT05445778 (ClinicalTrials.gov Identifier)Contact Person
Status
Recruiting
Disease Site
Ovarian
Lead Cooperative Group
Participating Groups
MaNGO
GINECO
CTI
BGOG
CEEGOG
ISGO
NCRI
GEICO